Lucy Goods is a technology company.
Lucy Goods has raised $10.0M across 1 funding round.
Lucy Goods has raised $10.0M in total across 1 funding round.
Lucy Goods has raised $10.0M in total across 1 funding round.
Lucy Goods's investors include Accel, UpHonest Capital, Vice Ventures, Y Combinator, Tom Blomfield.
Lucy Goods, Inc. is a consumer product company specializing in tobacco-free nicotine alternatives, including pouches, gums, lozenges, and flavored products designed to reduce tobacco-related harm.[1][2][5] Its mission is to alleviate harm from tobacco by switching users to cleaner, evidence-based pure nicotine products with food-grade ingredients, targeting adult smokers and nicotine users seeking focus, energy, or relaxation.[1][2][5] The company serves adults looking for convenient alternatives to combustible tobacco or traditional nicotine products, solving problems like health risks from smoking and suboptimal existing options through discreet, flavored formats.[1][3][5] Founded in 2016 and backed by Y Combinator (Winter 2018 batch), Lucy Goods has a team of about 7, remains active in Los Angeles, CA, and has pursued FDA approvals, including submitting Premarket Tobacco Product Applications (PMTAs) for 42 products in 2022.[1][2]
Lucy Goods was founded in 2016 by John Coogan, Samy Hamdouche, and David Renteln, with the company headquartered in Los Angeles.[1] John Coogan, an entrepreneur focused on the technology side of consumer packaged goods, brings expertise in computer graphics, deep learning, and marketing, and is an occasional angel investor.[1] The idea emerged from a harm-reduction approach to nicotine, emphasizing switching smokers from combustible tobacco to pure nicotine products rather than abstinence.[1][2][3] Early traction came via Y Combinator's Winter 2018 batch, establishing it as an active startup, followed by product launches like flavored gums and pouches, and active social media, podcasts, and AMAs to build awareness.[1][3]
Lucy Goods rides the wave of harm-reduction innovations in nicotine delivery, capitalizing on growing demand for tobacco-free alternatives amid rising awareness of vaping risks and smoking's health costs.[1][2][3] Timing aligns with FDA regulatory shifts, as seen in their 2022 PMTA submissions for 42 products, positioning them in the evolving oral nicotine market.[2] Market forces like public health pushes for reduced tobacco harm and consumer shift to discreet, flavored NRTs (nicotine replacement therapies) favor them, though challenges include youth appeal concerns from packaging mimicking gum.[3] As a Y Combinator alum, they contribute to the startup ecosystem by blending CPG tech with health tech, influencing nicotine product standards through FDA engagement and evidence-based advocacy.[1][3]
Lucy Goods is poised for growth through FDA marketing authorizations and expansion of its nicotine portfolio, potentially as a clinically proven cessation aid.[1][2] Trends like personalized nicotine routines, stricter tobacco regulations, and wellness-focused consumption will shape their path, amplifying harm-reduction impact if they navigate youth marketing scrutiny.[3][5] Their influence may evolve from niche innovator to mainstream player, reducing public health costs by converting smokers—tying back to their core mission of zero tobacco-related harm.[1][2]
Lucy Goods has raised $10.0M across 1 funding round. Most recently, it raised $10.0M Series A in February 2020.
| Date | Round | Lead Investors | Other Investors |
|---|---|---|---|
| Feb 1, 2020 | $10.0M Series A | Accel, UpHonest Capital, Vice Ventures, Y Combinator, Tom Blomfield |